Below is a summary of our recent news. Click any post title or the read more link below any story to see more!
Visit us on YouTube to view our new webinar: Graves' Disease, Thyroid Eye Disease and COVID-19 featuring Dr. Terry Smith and Dr. Don Kikkawa. (Approx. running time is 60 minutes).
Stuck at home? Connect with your fellow patients online! We have several formats available for online support, including oneGRAVESvoice (a collaboration between the GDATF, Horizon Therapeutics, and rareLife solutions), the GDATF's online support forum, and our closed Facebook group (click Join/Visit in the top right-hand corner of the screen). You can also contact a patient advocate at 877-643-3123 or [email protected]
Additional resources on COVID-19 that are specific to thyroid dysfunction and/or autoimmunity:
American Thyroid Association - Novel Coronavirus (COVID-19) and the Thyroid: Frequently Asked Questions
British Thyroid Foundation - Thyroid Disease and coronavirus (COVID-19)
The American Autoimmune Related Diseases Association has a number of resources (including recorded webinars) on their COVID-19 and Autoimmune Disease page.
In addition to your own state and county health departments, the following general resources will also hopefully be helpful:
Centers for Disease Control and Prevention (General Information)
Centers for Disease Control and Prevention - Stress and Coping
World Health Organization
Johns Hopkins Coronavirus Resource Center
Confused about the potential use of existing drugs as treatment options for COVID-19? This piece from the U.S. Food and Drug Administration explains the concept of "off-label" use and this article from the Centers for Disease Control lists potential therapeutic options for COVID-19. Use of these therapies must be supervised by a doctor; several deaths around the world have already occurred due to patients attempting to self-medicate.
The GDATF will continue to provide our community members with the latest information from credible sources. However, please be aware that this is a rapidly developing situation where guidance can change from day to day. Stay safe - and please check back for updates!
Please join us on Friday, April 24th at 2:00p EDT / 11:00a PDT for a special webinar: "Graves' Disease, Thyroid Eye Disease, & COVID-19." Featured presenters:
After reviewing new guidelines from UCSD regarding COVID-19, we have made the decision to postpone our Graves'/TED seminar, which was previously scheduled for 4/11.
The UCSD guidelines, which are effective through May 10th, "strongly recommend" cancellation or postponement of events that bring groups of more than 15 people to campus. You can read the UCSD guidance in full here:
Our intention is to reschedule this event as soon as it is deemed safe to do so.
BREAKING NEWS: The FDA has approved Tepezza (teprotumumab-trbw) for the treatment of adults with thyroid eye disease. Wiley Chambers, M.D., deputy director of the Division of Transplant and Ophthalmology Products in the FDA’s Center for Drug Evaluation and Research noted, “Today’s approval marks an important milestone for the treatment of thyroid eye disease. Currently, there are very limited treatment options for this potentially debilitating disease. This treatment has the potential to alter the course of the disease, potentially sparing patients from needing multiple invasive surgeries by providing an alternative, non surgical treatment option.” Read more from the FDA regarding research results, adverse reactions, and the FDA's review process.
On Friday, Dec. 13th, the FDA's Dermatologic and Ophthalmic Drugs Advisory Committee met in Silver Spring, MD to discuss teprotumumab, a potential treatment for active thyroid eye disease.